We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

19 hedge funds and large institutions have $7.85M invested in vTv Therapeutics in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

883% more capital invested

Capital invested by funds: $798K → $7.85M (+$7.05M)

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

36% more funds holding

Funds holding: 14 → 19 (+5)

10.32% more ownership

Funds ownership: 3.41% → 13.73% (+10%)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

Holders
19
Holders Change
+5
Holders Change %
+35.71%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
5
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
+$2.11M
2
BBA
Baker Bros. Advisors
New York
+$1.24M
3
UBS Group
UBS Group
Switzerland
+$18.5K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$13.2K
5
PCMC
Planning Capital Management Corporation
Pennsylvania
+$7.95K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$10.7K
2
TRCT
Tower Research Capital (TRC)
New York
-$6.8K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$6.16K
4
BlackRock
BlackRock
New York
-$3.33K
5
FWM
Focused Wealth Management
New York
-$2.88K
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$4.87M +$2.11M +165,896 +406%
BBA
2
Baker Bros. Advisors
New York
$2.29M +$1.24M +97,314 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$578K +$13.2K +1,039 +4%
UBS Group
4
UBS Group
Switzerland
$34.3K +$18.5K +1,457 New
BlackRock
5
BlackRock
New York
$25.4K -$3.33K -262 -20%
Morgan Stanley
6
Morgan Stanley
New York
$19.8K -$10.7K -840 -50%
PCMC
7
Planning Capital Management Corporation
Pennsylvania
$14.7K +$7.95K +625 New
TRCT
8
Tower Research Capital (TRC)
New York
$12.6K -$6.8K -535 -50%
Osaic Holdings
9
Osaic Holdings
Arizona
$3.53K +$1.27K +100 +200%
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$2K -$6.16K -484 -82%
Bank of America
11
Bank of America
North Carolina
$1.79K +$954 +75 +7,500%
PA
12
Parallel Advisors
California
$894 – – –
Wells Fargo
13
Wells Fargo
California
$682 -$13 -1 -3%
CPG
14
Cornerstone Planning Group
New Jersey
$449 – – –
SS
15
Sunbelt Securities
Texas
$353 – – –
Fidelity Investments
16
Fidelity Investments
Massachusetts
$259 +$140 +11 New
BNP Paribas Financial Markets
17
BNP Paribas Financial Markets
France
$212 +$114 +9 New
CTC
18
Central Trust Company
Missouri
$118 +$64 +5 New
JP Morgan Chase
19
JP Morgan Chase
New York
$47 +$13 +1 +100%
FWM
20
Focused Wealth Management
New York
– -$2.88K -250 Closed

VTVT Hedge Fund Activity: Q1 2024 in Review

19 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2024, worth a combined $7.85M — up 883% from $798K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new VTVT positions and 1 closed out — a net gain of 5 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was Samsara BioCapital, adding an estimated $2.11M. The largest seller was Morgan Stanley, cutting an estimated $10.7K.

  • 19 institutional investors held vTv Therapeutics (VTVT) as of Q1 2024, up from 14 in Q4 2023.
  • Funds reported $7.85M of vTv Therapeutics stock for Q1 2024, up 883% quarter-over-quarter.
  • 6 funds opened new vTv Therapeutics positions in Q1 2024 and 1 closed out, a net change of +5 holders.
  • The largest vTv Therapeutics buyer in Q1 2024 was Samsara BioCapital, an estimated $2.11M added.
  • The largest vTv Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $10.7K sold.

Based on aggregated 13F filings for Q1 2024.